Related Experiment Video
Updated: Mar 11, 2026
06:53
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
3.3K
SEOM Clinical Guideline for bone metastases from solid tumours (2016)
C Grávalos1, C Rodríguez2, A Sabino3
1Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. cristina.gravalos@salud.madrid.org.
Summary
Bone metastases, common in advanced cancers, cause skeletal-related events (SREs). This guideline reviews diagnosis and management, including bone-targeted therapies and local treatments, to improve patient quality of life.
Area of Science:
- Oncology
- Medical Guidelines
- Skeletal Metastasis Research
Background:
- Bone metastases are prevalent in advanced solid tumors like breast, prostate, lung, thyroid, and renal cancers.
- These metastases can lead to significant complications, termed skeletal-related events (SREs), including fractures, spinal cord compression, and hypercalcemia.
- Patients often suffer from pain, functional decline, and reduced quality of life due to bone metastases.
Purpose of the Study:
- To provide a comprehensive review of bone metastases, covering pathogenesis, clinical presentation, and diagnostic imaging.
- To outline current bone-targeted therapies, such as bisphosphonates and monoclonal antibodies, and local treatments like radiation and surgery.
- To establish evidence-based recommendations for managing patients with bone metastases.
Main Methods:
- Review of pathogenesis, clinical presentations, laboratory tests, and imaging techniques for diagnosis and response assessment.
- Analysis of bone-targeted agents including zoledronic acid, denosumab, and radium-223.
- Evaluation of local therapies such as bone surgery and radiotherapy.
Main Results:
- Bone-targeted therapies (zoledronic acid, denosumab) effectively reduce the risk and delay the development of SREs across various cancer types.
- Radium-223 has demonstrated improved overall survival in castration-resistant prostate cancer with bone metastases.
- A multidisciplinary approach integrating systemic therapies, local treatments, and supportive care is crucial for optimal management.
Conclusions:
- Effective management of bone metastases requires a thorough understanding of their pathogenesis and clinical impact.
- Current therapeutic strategies, including bone-targeted agents and local interventions, can significantly mitigate SREs and improve patient outcomes.
- Adherence to multidisciplinary guidelines is essential for optimizing the care of patients with bone metastases.
